MINERALYS THERAPEUTICS INC

Mineralys Therapeutics (MLYS) shares slip 2.2% after Phase‑3 lorundrostat shows 50% albumin‑to‑creatinine reduction in hypertensive CKD patients, eyeing FDA approval.

Mineralys Therapeutics (MLYS) dips 2.2% at $21.47: 1.9B cap, 200‑day SMA $27.45, YTD -28% vs peers, focus on aldosterone synthase inhibitors.

Mineralys Therapeutics (MLYS) gains 3.15% as board expands, adding new directors with equity awards, hinting at a potential rebound in its biopharma stock.

Mineralys Therapeutics (MLYS) expands its board, aligns director compensation with long‑term value, and eyes a potential rebound as clinical milestones approach.